DiaSorin (OTCMKTS:DSRLF) Shares Gap Down – Time to Sell?

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s share price gapped down before the market opened on Monday . The stock had previously closed at $80.40, but opened at $77.58. DiaSorin shares last traded at $77.58, with a volume of 20 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, June 17th. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. BNP Paribas Exane lowered shares of DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. Zacks Research raised DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Finally, Piper Sandler began coverage on DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating on the stock. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

DiaSorin Stock Down 3.5%

The business has a fifty day simple moving average of $76.08 and a 200-day simple moving average of $76.38.

About DiaSorin

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.